Breaking news and a victory for psychedelic advocates as the DEA has reversed its decision to schedule 5 psychedelic substances.
In January, we reported that the DEA was moving to criminalize new psychedelics (War on Drugs Update: DEA to Expand List of Banned Psychedelics).
Despite their medical potential, the DEA announced that it was adding 5 drugs to Schedule 1 of the Controlled Substances Act, the most restrictive legal class of drugs reserved for substances with a high abuse potential and no use currently accepted medical. The five compounds, all tryptamines, are:
4-hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT), 5-methoxy-alphamethyltryptamine (5-MeO-AMT), N-isopropyl-5-methoxy-N-methyltryptamine (5-MeO-MiPT), N ,N-diethyl-5-methoxytryptamine (5-MeO-DET) and N,N-Diisopropyltryptamine (DiPT).
But there was considerable public pushback, and advocates and researchers seized the opportunity to plead their cases Public hearing of the DEA. And it seems to have worked as the DEA has withdrawn its proposed rule.
Here are comments and insights from Graham Pechenik, a patent attorney who served as co-counsel in this case.
This is great news not only for this particular case, but for the future of psychedelic reform, as the DEA appears to be listening to the experts…
5 psychedelic tryptamines, not scheduled?
DEA Programming Procedures: Completed:
“DEA is withdrawing the proposed rule … canceling the public hearing and ending the pending hearing process”
Unprecedented Result: An Extraordinary Lawyer Result by Matt Zorn
1/2 pic.twitter.com/OJHjhcDNil
— Graham Pechenik (@calyxlaw) July 22, 2022
Congratulations to the challengers @TactogenInc & @MindstateDesign
With many thanks also to the expert statements of @AndrewChadeayne & @ProfDavidNutt
I am grateful to have been a co-advisor with Matt as science and common sense carry the day
2/2
— Graham Pechenik (@calyxlaw) July 22, 2022
